Alnylam Pharmaceuticals Inc (ALNY.OQ)
20 Oct 2017
Oct 18 Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.
Oct 18 Drug developer Alnylam Pharmaceuticals Inc entered into an agreement with privately held Vir Biotechnology on Wednesday to develop a new class of RNAi-based treatments for infectious diseases, including chronic hepatitis B.
Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.
* Alnylam and Vir form strategic alliance to advance RNAi therapeutics for infectious diseases
* Alnylam initiates phase 2 clinical study of cemdisiran (ALN-CC5) in patients with atypical hemolytic-uremic syndrome (aHUS)
Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease-causing proteins.
* $1 bln peak sales expected for patisiran in 2023 - Credit Suisse
* Sanofi and Alnylam report positive topline results from APOLLO phase 3 study of patisiran in Hereditary ATTR (HATTR) amyloidosis patients with polyneuropathy
Sept 20 Alnylam Pharmaceuticals Inc said on Wednesday its drug met the main goal in a late-stage study in patients suffering from a life-threatening genetic disease.
Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies after one patient died, sending its shares sharply down.
|Merck & Co., Inc. (MRK.N)||$63.88||+0.13|
|Takeda Pharmaceutical Co Ltd (4502.T)||¥6,326||-9.00|
|Silence Therapeutics plc (SLN.L)||244.00||+9.00|
|Arbutus Biopharma Corp (ABUS.OQ)||$6.50||+0.10|
|Rosetta Genomics Ltd. (USA) (ROSG.OQ)||$0.90||+0.00|
|Sarepta Therapeutics Inc (SRPT.OQ)||$51.94||+1.22|
|Kyowa Hakko Kirin Co Ltd (4151.T)||¥2,022||+3.00|
|Pfizer Inc. (PFE.N)||$36.42||+0.18|
|AstraZeneca plc (AZN.L)||5,162.00||-13.00|
|Bayer AG (BAYGn.DE)||€117.95||-0.75|